Sanofi, a global leader in life science consulting, is making headway in Morocco, Tunisia, and Libya. Spearheaded by Adrien Delamare-Deboutteville, Sanofi’s mission is to enhance access to innovative therapies, reflecting the company’s commitment to value-based healthcare. This initiative aligns with Morocco’s grand vision of universal healthcare, a transformative goal that seeks to double the number of Moroccans covered by health insurance from 22 million to 44 million.
Innovation is at the heart of Morocco’s healthcare transformation. The country is making strides in integrating innovative therapies into their healthcare system, a testament to their commitment to improving patient outcomes. However, the journey is not without its challenges. It requires not only the development of innovative therapies but also the building of capabilities, competencies, and infrastructure. Sanofi is at the forefront of this movement, committed to bringing more innovative solutions to the market and ensuring they are integrated into the healthcare system.
Sanofi sets itself apart with its patient-first ethos. This approach was evident during the challenging period of war in Ukraine, where Delamare-Deboutteville and his team ensured the continuous operation of Sanofi’s Ukraine offices. Their dedication to their patients was paramount, demonstrating the resilience and commitment that defines Sanofi.
Their patient-centric approach is also evident in Morocco. Therefore, the company is keen to contribute to the evolution of Morocco’s healthcare ecosystem. They are working hand in hand with other stakeholders to implement the universal healthcare system. Sanofi’s strategy is built around bringing more innovation to the market. The company aims to transform the practice of medicine through breakthrough science, positively impacting people and communities. Their initiatives in Morocco include the My Child Matters program, supporting children with cancer, and the KiDS initiative, fostering a better understanding of diabetes in school environments.
In conclusion, the aspiration for future interactions is to ensure that the broader pharmaceutical industry, plays a pivotal role in shaping Morocco’s universal healthcare system. The ultimate goal is to become an integral part of this healthcare revolution in Morocco.
💊 Could MFN Pricing Undermine Biosimilars?
MFN drug pricing aims to cut costs—but its indirect pressure on biosimilars may reduce competition (create a void) and raise long-term prices.
Explore the risks and what stakeholders can do to protect market sustainability.
#SyenzaNews #Biosimilars #DrugPricing #HealthPolicy #Pharma #MarketAccess
🔍 Are you prepared for the upcoming EU AI Act in healthcare?
As the first comprehensive AI regulation globally rolls out, healthcare organizations must move beyond mere compliance. The urgency lies in embedding ethical, trusted, and sustainable AI practices into every facet of healthcare AI. Early adoption of ethical assessments and collaboration is essential to navigate the complex regulatory landscape before the August 2026 deadline.
Learn about proactive compliance strategies that not only meet regulatory standards but also enhance patient trust and system efficacy!
#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation
💉 Are we doing enough to bridge the gap in hepatitis vaccine uptake?
A recent article highlights that while over 90% of children are vaccinated against hepatitis B, adult rates are alarmingly low, posing a significant public health risk. Jeff Goad from the National Foundation for Infectious Diseases emphasizes the crucial role pharmacists can play in increasing access and dispelling common misconceptions about vaccines.
Join the conversation on enhancing vaccination strategies for better health outcomes!
#SyenzaNews #Healthcare #HealthEconomics
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
